search
Back to results

Perfusion - Pressure - Creatinine Trial (PPC)

Primary Purpose

Acute Kidney Injury

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
MAP > 60 mmHg
Sponsored by
Rigshospitalet, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Acute Kidney Injury focused on measuring Renal insufficiency, Acute Kidney Injury, Postoperative, Extracorporeal Circulation, Heart surgery

Eligibility Criteria

70 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > 70
  • Combined procedures (heart valve-, bypass- and aortic aneurysm surgery)

Exclusion Criteria:

  • Age < 70
  • S-creatinine > 200 µmol/L
  • Acute operation
  • Endocarditis

Sites / Locations

  • Department of Cardiothoracic Surgery, Rigshospitalet

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Active Comparator

Arm Label

Standard blood pressure

MAP > 60 mmHg

Arm Description

Extracorporeal circulation during the surgery are conducted using standard blood pressure

A blood pressure of MAP > 60 mmHg is used during extracorporeal circulation. The higher MAP is maintained by using continuous intravenous administration of norepinephrine titrated to the appropriate dose for each patient.

Outcomes

Primary Outcome Measures

Glomerular Filtration Rate measured the day before surgery compared to 4 - 6 days and 4 months (+/- 14 days) postoperative
Measured by means of Cr-EDTA clearance

Secondary Outcome Measures

Renal oxygen consumption measured minutes before surgery compared to intraoperative, 6 hours postoperative and 8.00 a.m. the day after surgery
Measured as difference in saturation of blood gas measurements from the renal vein catheter and radial artery.
neutrophil gelatinase-associated lipocalin (NGAL) measured just before anaesthesia compared to just after extracorporal perfusion has ended, 6 hours postoperatively, 8.00 a.m. the day after surgery, 2nd and 5th day
Measured in urine samples
Renal renin and proANP excretion measured the day before surgery compared to just after induction of anaesthesia, directly after extracorporeal perfusion has begun, just before extracorporeal perfusion ends, 1st and 5th postoperative day
Measured from the renal vein catheter and venous blood sample
Serum Cystatin C measured the day before surgery compared to directly after induction of anaesthesia, directly after extracorporeal perfusion has begun, just before extra corporeal perfusion has ended, 1st and 5th day postoperative
Measured from standard blood sample.

Full Information

First Posted
July 19, 2011
Last Updated
March 26, 2014
Sponsor
Rigshospitalet, Denmark
Collaborators
Danish Heart Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT01408420
Brief Title
Perfusion - Pressure - Creatinine Trial
Acronym
PPC
Official Title
Impact of Perfusion Pressure During Extracorporeal Circulation on Postoperative Kidney Function
Study Type
Interventional

2. Study Status

Record Verification Date
March 2014
Overall Recruitment Status
Completed
Study Start Date
April 2011 (undefined)
Primary Completion Date
January 2014 (Actual)
Study Completion Date
March 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark
Collaborators
Danish Heart Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In Denmark around 3500 procedures are conducted involving a heart-lung-machine per year. An increase in the prevalence of postoperative kidney insufficiency have been observed following these procedures, during the last years. Kidney related complications are associated with a higher mortality and morbidity. The reason and mechanisms behind this impaired kidney function is unknown. One possible cause could be that the blood pressure used in the heart-lung-machine is too low, during surgery. In the PPC trial we plan to include 100 patients. One half of the patients are operated with a normal, lower, blood pressure on the heart-lung-machine. The other half receives a blood pressure of > 60 mmHg during surgery. The primary goal of the trial is to measure the kidney function (GFR) the day before surgery compared to day 4 - 6 and 4 months (+/- 14 days) after surgery. During the surgery a catheter is inserted through the femoral vein into the kidney vein. This makes it possible to measure several biochemical markers and the oxygen consumption of the kidney, during the surgery. Urine samples are also collected and analyzed. The study hypothesis: The glomerular filtration rate (GFR) is better preserved after cardiac surgery with extra corporal circulation with an intended increased periprocedural arterial blood pressure compared to current practice.
Detailed Description
Introduction: Renal function and cardiac surgery Impaired kidney function is a well known complication to cardiac surgery and is observed in up to 30% of the patients, depending on the definition of acute kidney injury (AKI). The precise pathophysiological mechanisms are unknown, it is, however, quite obvious that AKI is not initiated by a single harmful factor but seems to be the result of different combined factors. Known risk factors for the development of postoperative AKI are cardiac incompensation, poor ejection fraction, gender, chronic obstructive lung disease, insulin dependent diabetes mellitus (IDDM), previous heart surgery, acute surgery, complexity of surgery, preoperative creatinine levels and prolonged duration of extracorporeal perfusion. These associations are not necessarily causal. It is not surprising that a subacute operation for a severe aortic stenosis in a patient with preoperatively poor circulation and a marginally increased S-creatinine, results in impaired renal function postoperatively. However, to conclude that cardiac surgery is the reason for AKI is not justified. Several peroperative factors are likely to contribute in the development of AKI. Renal perfusion and oxygen delivery might be reduced (hypotension, lack of pulsatile flow during extracorporeal circulation (ECC), vasoactive pharmacological agents, anaesthesia), risk for emboli, general inflammatory response, direct nephrotoxins (free haemoglobin, free radicals, gentamycin etc.) and haemodilution. Current knowledge is limited and the general insight into regional perfusion during extracorporeal perfusion (heart-lung-machine) is very sparse. There do, however, exist guidelines regarding flow and blood pressure during ECC, but these are based upon empiric data, which are controversial and vary from centre to centre. The primary focus has been on regional cerebral perfusion and the possibilities to reduce the frequency of cerebral complications after cardiac surgery. This interest can easily be explained by the obvious catastrophic consequences for the patient due to coma, hemiparesis or serious cognitive dysfunction. The consequences of AKI are less evident, however there is a direct and strong association between a moderately increased postoperative creatinine level, reduced glomerular filtration rate (GFR) and 30 day mortality as long term survival. A recent analysis of the kidney function of lung transplanted patients in our department after use of ECC showed that GFR was dramatically reduced by 40% 14 days after surgery. This impairment has furthermore been shown to be irreversible. Cyclosporine A is known to be nephrotoxic in the long term, but this can hardly explain the observed GFR reduction after 14 days, which must result from the combined influence of surgical/anaesthesiological trauma, cyclosporine, and side effects of antibiotic, antiviral, antifungal and immunosuppressive treatment. Data from our internal prospective registry shows an increasing incidence of patients with renal complications. In 2008 temporary dialysis was necessary in 7% of the patients (76/1130) and in 19% of the patients a postoperative increase of S-creatinine > 200 μmol/l was observed, mirroring a reduction in kidney function of 60-70%. We assume that the kidney function is completely normalized over time, but this is actually not known because these patients are not routinely controlled on a cardiac surgery outpatient basis. Currently, we are gathering 1-year outcome data on patients, who have undergone postoperative dialysis in 2008. One of the reasons for the increasing frequency of AKI might be increasing patient age, and thereby, an increase in comorbidity. At the same time the administration of ECC has changed. Ten years ago patients were routinely cooled during ECC. This is not the case anymore and results in a reduced degree of peripheral vessel constriction and consequently reduced blood pressure. The question regarding which blood pressure and which blood flow is optimal during ECC remains controversial, but generally a much lower blood pressure is now accepted, as long as the calculated blood flow is maintained and cerebral saturation values are sufficient (not measured routinely). The literature on the subject is sparse but two randomized trials exists. One had a primary focus on kidney autoregulation at different perfusion pressures, the other recent trial could not demonstrate significant differences in kidney function measured by s-creatinine at 3 different perfusion pressures. However, S-creatinine is a very crude method for measuring kidney function. In addition, the trial included patients with low risk of postoperative AKI. Postoperative increase in S-creatinine typically occurs on day 2 or 3 after surgery, and S-creatinine does not increase before GFR is reduced below 50%. This implies that the possible initial 50% reduction in kidney function cannot be detected by routine biochemistry. It is fair to assume that kidney injury occurs during surgery or within the first postoperative 24 hours. From a biochemical point of view there is an apparent lack of robust and reliable early markers of tubular kidney damage, which would allow a relevant early clinical intervention, and possible prevention of AKI aggravation. Creatinine kinases MB and troponins are very reliable markers for cardiac damage and can reveal acute myocardial infarction within hours after the occlusion of coronary vessels. A corresponding early diagnosis of AKI does not exist. At the same time it seems likely that specific enzymatic or cell membrane components could be detectable in the urine a few hours after an AKI. There has been some focus on possible candidates for early detection of AKI, but none have shown to be sufficiently robust for clinical use, yet. During the last 20 years there have been a few trials with focus on prevention and prophylactic intervention to avoid AKI with anti-inflammatory drugs, natriuresis inducing agents (ANP) or renal blood flow increasing pharmacological intervention. However, none of these interventions have had sufficiently convincing effects for further clinical testing. A recent Japanese study seems to indicate that prophylactic infusion of ANP can reduce postoperative kidney impairment, but these results need confirmation. Our department is currently performing a phase 2 trial in cooperation with Action Pharma (a Danish biotech company) in which we are testing AP214, a new small anti-inflammatory protein, with potential kidney protective characteristics (clinicaltrials.gov: 00903604). At the same time we are investigating if AP214 can reduce the nephrotoxic effect of cyclosporine in a pig kidney transplant model. Summary / Conclusion: An increasing incidence of renal complications is seen after cardiac surgery. The aetiology is unknown. It is unclear if the reduction in renal function is reversible. Renal complications are associated with increased short- and long term mortality and morbidity after cardiac surgery. Renal regional perfusion during extracorporeal circulation is poorly understood, and the impact of blood pressure and perfusion on postoperative kidney function in patients with increased risk for AKI after cardiac surgery is unknown. There are several potential biochemical markers for the early detection of acute tubular kidney damage, however there is a substantial lack of clinical data. Several interventions might be kidney protective, however there are no robust clinical data. Hypothesis for the PPC trial The glomerular filtration rate (GFR) is better preserved after cardiac surgery with ECC with an intended increased periprocedural arterial blood pressure compared to current practice. Methods Design: Phase 1: Randomized proof of concept trial, n = 12. Simple 1:1 randomisation. Phase 2: If the proof of concept trial turns out positive and logistically feasible (which we have shown, see later) the trial will be extended to include 2 x 50 patients. There are no similar trials or data in the literature on which to base an estimate of the necessary trial size. N = 100 is a qualified assumption based on what is clinically possible to include within a 1-1½ year period. As earlier shown in the lung transplant population GFR was reduced with 40%. A clinically relevant improvement of an average reduction in GFR would be a reduction of 20%. However, GFR data are quite heterogeneous and some patients have perfectly normal GFR's throughout surgery and the postoperative course, while others develop pronounced AKI. Phase 3: Test of different preventive and prophylactic interventions (AP214, proANP, reduced haemodilution, pulsatile flow during ECC). Trial size and outcome measures will be dependent on results from phase 2. There are no earlier data on continuous saturation measurement in renal venous blood or sequential mass spectrometric analysis of urine in a cardiac surgery population. Current results will therefore decide on future primary outcome measures. Inclusion- and exclusion criteria: Patients with increased risk of postoperative AKI, who give written consent after appropriate information, are included. Inclusion criteria are: Age > 70 Combined procedures (heart valve-, bypass surgery and aortic aneurysm) Exclusion criteria are: Age < 70 S-creatinine > 200 µmol/L Acute operation Endocarditis Intervention: Control group: Operation procedure and ECC run are performed according to current guidelines at the Dept. of Thoracic and Cardiovascular Surgery / Rigshospitalet. Intervention group: During ECC run a MAP > 60 mmHg is maintained. In both groups GFR measurements are performed using the Cr-EDTA clearance method. GFR is measured the day before surgery, day 4-6 after surgery and finally after 4 months (+/- 14 days). A catheter is inserted in the renal vein through the femoral vein. The position is controlled by fluoroscopy. Repeated saturation measurements, by blood gas analysis, will be performed during and in the first 24 hours after surgery. Blood samples are taken from the same access. The catheter is removed before discharge from the intensive care unit. Outcome measures: Primary outcome measure: Cr-EDTA clearance, the day before surgery, at day 4 - 6 and 4 months (+/- 14 days) after surgery Secondary outcome measures: Oxygen consumption on-line in renal venous blood Renal renin and proANP excretion U-NGAL, U-Apolipoprotein M, U-IL-18, U-KIM-1 and S-cystatin C Urine proteomics (mass spectrometry) Tertiary outcome measures: Standard clinical data collection (haemodynamics, diuresis, routine biochemistry) and clinical outcome in terms of time in intensive care, time to discharge, incidence rates of adverse- and serious adverse events. Economy: This investigation is a non-profit trial. None of the project members have economic interests in the trial. The involved clinical departments cover direct and indirect expenses regarding the prolonged admission, GFR-measurements and additional biochemical analyses estimated to be 15.800 DKK per patient. The Danish Heart Association covers the salary for Ph.D. student Kristian Kandler. 5: Perspectives This project combines expert knowledge from different medical fields on a highly scientific and clinical level (advanced cardiac surgery in high risk patients, advanced postoperative intensive care, innovative monitoring (invasive, biochemical, clinical physiology). We expect to provide original, innovative and scientifically relevant results that will contribute to a better understanding of the renal pathophysiology and autoregulation during and after cardiac surgery. As a clinical randomised trial this study may show new possibilities to reduce the incidence of postoperative renal complications in a group of patients with significant mortality and morbidity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Kidney Injury
Keywords
Renal insufficiency, Acute Kidney Injury, Postoperative, Extracorporeal Circulation, Heart surgery

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard blood pressure
Arm Type
No Intervention
Arm Description
Extracorporeal circulation during the surgery are conducted using standard blood pressure
Arm Title
MAP > 60 mmHg
Arm Type
Active Comparator
Arm Description
A blood pressure of MAP > 60 mmHg is used during extracorporeal circulation. The higher MAP is maintained by using continuous intravenous administration of norepinephrine titrated to the appropriate dose for each patient.
Intervention Type
Procedure
Intervention Name(s)
MAP > 60 mmHg
Intervention Description
During heart surgery a blood pressure with a MAP > 60 mmHg during extracorporeal circulation is used.
Primary Outcome Measure Information:
Title
Glomerular Filtration Rate measured the day before surgery compared to 4 - 6 days and 4 months (+/- 14 days) postoperative
Description
Measured by means of Cr-EDTA clearance
Time Frame
The day before surgery, 4 - 6 days and 4 months (+/- 14 days) postoperative
Secondary Outcome Measure Information:
Title
Renal oxygen consumption measured minutes before surgery compared to intraoperative, 6 hours postoperative and 8.00 a.m. the day after surgery
Description
Measured as difference in saturation of blood gas measurements from the renal vein catheter and radial artery.
Time Frame
Directly after placement of the renal vein catheter and every 15 minutes during surgery. 6 hours after surgery and 8.00 a.m. the day after surgery.
Title
neutrophil gelatinase-associated lipocalin (NGAL) measured just before anaesthesia compared to just after extracorporal perfusion has ended, 6 hours postoperatively, 8.00 a.m. the day after surgery, 2nd and 5th day
Description
Measured in urine samples
Time Frame
Before induction of anaesthesia in the operating room, directly after the extracorporeal perfusion has ended. 6 hours postoperative. 8.00 a.m. the day after surgery. 2nd and 5th day postoperative.
Title
Renal renin and proANP excretion measured the day before surgery compared to just after induction of anaesthesia, directly after extracorporeal perfusion has begun, just before extracorporeal perfusion ends, 1st and 5th postoperative day
Description
Measured from the renal vein catheter and venous blood sample
Time Frame
The day before surgery. Directly after induction of anaesthesia. Directly after extracorporeal perfusion has begun. Just before extra corporeal perfusion is ended.1st and 5th day postoperative
Title
Serum Cystatin C measured the day before surgery compared to directly after induction of anaesthesia, directly after extracorporeal perfusion has begun, just before extra corporeal perfusion has ended, 1st and 5th day postoperative
Description
Measured from standard blood sample.
Time Frame
The day before surgery. Directly after induction of anaesthesia. Directly after extracorporeal perfusion has begun. Just before extra corporeal perfusion has ended.1st and 5th day postoperative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > 70 Combined procedures (heart valve-, bypass- and aortic aneurysm surgery) Exclusion Criteria: Age < 70 S-creatinine > 200 µmol/L Acute operation Endocarditis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel A Steinbrüchel, Professor
Organizational Affiliation
Department of Cardiothoracic Surgery, Rigshospitalet, Denmark
Official's Role
Study Chair
Facility Information:
Facility Name
Department of Cardiothoracic Surgery, Rigshospitalet
City
Copenhagen East
State/Province
Copenhagen
ZIP/Postal Code
2100
Country
Denmark

12. IPD Sharing Statement

Citations:
PubMed Identifier
31196131
Citation
Kandler K, Nilsson JC, Oturai P, Jensen ME, Moller CH, Clemmesen JO, Arendrup HC, Steinbruchel DA. Higher arterial pressure during cardiopulmonary bypass may not reduce the risk of acute kidney injury. J Cardiothorac Surg. 2019 Jun 13;14(1):107. doi: 10.1186/s13019-019-0929-4.
Results Reference
derived

Learn more about this trial

Perfusion - Pressure - Creatinine Trial

We'll reach out to this number within 24 hrs